CHARLES H. SHERWOOD, PH.D. - Corporate Board Profile

Anika Therapeutics, Inc.

Filing Date	Source Excerpt
2003-04-30	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002. Dr. Sherwood has served as President since June 2001. Dr. Sherwood previously served as Anika Therapeutics' Chief Operating Officer beginning in June 2001, Vice President of Research and Development beginning in April 2000 and Vice President of Process Development and Engineering beginning in April 1998. The following table sets forth certain information concerning the compensation, for each of the periods indicated, of the individuals who have served as Anika Therapeutics' Chief Executive Officer and the four most highly compensated executive officers for the year ended December 31, 2002. Charles H. Sherwood President and Chief Executive Officer 2002 Salary $246,585 Bonus $75,000 All Other Compensation $10,727.
2004-04-29	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002. He serves as President and CEO and is not considered independent by the Board. Compensation for non-employee Directors in 2003 was $10,000 cash and options valued at $10,000, but Dr. Sherwood is an employee and his compensation is detailed separately under executive officers.
2005-04-29	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002. Dr. Sherwood has served as President since June 2001. Dr. Sherwood previously served as Anika Therapeutics' Chief Operating Officer beginning in June 2001, Vice President of Research and Development beginning in April 2000 and Vice President of Process Development and Engineering beginning in April 1998. Dr. Sherwood was also a part-time faculty member in the Department of Chemistry at the California State Polytechnic University, Pomona, California from 1984 to 1987. Dr. Sherwood received a B.S. in Chemical Engineering from Cornell University, and a M.S. and Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Amherst. Dr. Sherwood also received a Certificate in Management from Claremont Graduate School. The Board of Directors has determined that each of its incumbent members, except for Dr. Sherwood, is "independent" for purposes of the Rule 4200(a)(15) of the National Association of Securities Dealers and Nasdaq listing standards.
2006-04-24	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002. Dr. Sherwood has served as President since June 2001. Dr. Sherwood is not considered independent by the Board. No director compensation is mentioned for Dr. Sherwood as he is an employee.
2007-04-27	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002. Dr. Sherwood has served as President since June 2001. The following table summarizes the compensation information in respect of NEOs for the fiscal year ended December 31, 2006. Charles H. Sherwood President and Chief Executive Officer Total Compensation: $927,681.
2008-04-25	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002. Dr. Sherwood has served as President since June 2001. The Board of Directors has determined that each of its incumbent members, except for Dr. Sherwood, is "independent". Dr. Sherwood is also an executive officer and does not receive director compensation.
2009-04-28	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002. Dr. Sherwood has served as President since June 2001. Dr. Sherwood previously served as Anika Therapeutics' Chief Operating Officer beginning in June 2001, Vice President of Research and Development beginning in April 2000 and Vice President of Process Development and Engineering beginning in April 1998. Dr. Sherwood served as a consultant to Anika Therapeutics from January 1998 to April 1998. Dr. Sherwood received a B.S. in Chemical Engineering from Cornell University, and an M.S. and Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Amherst.
2010-04-22	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002 and has served as President since June 2001. He is not considered independent. No specific director compensation is listed for him as he is an executive officer.
2011-04-28	Dr. Sherwood was appointed CEO in 2002 and President in 2001. His total compensation for 2010 was $1,015,270.
2012-04-25	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002 and has served as President since June 2001. The Summary Compensation Table shows that Charles H. Sherwood, Ph.D. received total compensation of $1,479,955 in 2011.
2013-04-23	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002. Dr. Sherwood has served as President since June 2001. ... The Board of Directors has determined that each of its incumbent members, except for Dr. Sherwood, is “independent” ... Dr. Sherwood’s biography is included above in the section titled “Information Regarding the Directors.” ... The following table summarizes the compensation information in respect of our NEOs for the year ended December 31, 2012, comprised of our Chief Executive Officer, Chief Financial Officer and Chief Operating Officer. ... Charles H. Sherwood, Ph.D. 2012 Salary $505,447, Bonus $303,438, Total $841,477.
2014-04-23	Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002, and became a member of the Board of Directors. Dr. Sherwood has served as President since June 2001. The Board of Directors has determined that each of its incumbent members, except for Dr. Sherwood, is “independent” within the meaning of director independence standards of the NASDAQ Stock Market, Inc. (“NASDAQ”) and the SEC. Dr. Sherwood is not independent. No specific director compensation is listed for Dr. Sherwood as he is an executive officer.
2015-04-23	Charles H. Sherwood, Ph.D., was appointed Chief Executive Officer of Anika Therapeutics in March 2002, and simultaneously became a member of the Board of Directors. Dr. Sherwood has served as President since June 2001. The Summary Compensation Table shows Dr. Sherwood’s total compensation for 2014 was $2,230,367.
2016-04-20	Charles H. Sherwood, Ph.D., was appointed Chief Executive Officer of Anika Therapeutics in March 2002, and simultaneously became a member of the Board of Directors. He is not listed as serving on any committees. His compensation is detailed under executive officers, not as a director.
2017-04-28	Charles H. Sherwood, Ph.D., was appointed Chief Executive Officer of Anika Therapeutics in March 2002, and simultaneously became a member of the Board of Directors. Dr. Sherwood has served as President since June 2001. Dr. Sherwood previously served as Anika Therapeutics’ Chief Operating Officer beginning in June 2001, Vice President of Research and Development beginning in April 2000, and Vice President of Process Development and Engineering beginning in April 1998. Dr. Sherwood served as a consultant to Anika Therapeutics from January 1998 to April 1998. From 1995 to 1997, Dr. Sherwood was Senior Director of Medical Device Research and Development for Chiron Vision. In April 1995, Chiron Vision acquired IOLAB Corporation, a division of Johnson & Johnson where Dr. Sherwood had been Executive Director of Research and Development from 1993 to 1995, Director of Materials Characterization from 1989 to 1993, and Manager/Section Head from 1982 to 1989. Dr. Sherwood was also a part-time faculty member in the Department of Chemistry at the California State Polytechnic University, Pomona, California from 1984 to 1987. Dr. Sherwood received a B.S. in Chemical Engineering from Cornell University, and an M.S. and Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Amherst. Dr. Sherwood also received a Certificate in Management from Claremont Graduate School. Dr. Sherwood brings to the Board an exceptional understanding of all aspects of our business given his role as our President and Chief Executive Officer, and he provides invaluable insight to the Board with respect to their decision-making functions.